Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Legal & General Assurance Society Limited (“Legal & General”) has completed a £1.4 billion buy-in with the Sanofi Pension Scheme (“the Scheme”), securing the benefits of 4,900 retirees and 5,600 ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

Aventis Pharma has appointed Mr.Ramesh Subramanian, MD as the Vice-president of the Respiratory Sales for North-East and Mid-Atlantic US. 2004 -Aventis ... of the sanofi-aventis Group and Mr ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

The company received sale consideration of Rs 100.75 crore (equivalent to US Dollars 22.399 million).On 24 August 2011, Aventis Pharma Limited (part of the Sanofi Group) announced that it has ...

Out of the entirety of a constellation shines brightest, the North Star. Likewise exist merely a handful of people; the cream of the crop, whose hard work, resilience, aspiration and grey matter ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...